Clinical trials: Recurrent Hepatocellular Cancer
Hepatocellular Carcinoma, Tumor Recurrence
Effect of Babaodan on Tumor Recurrence After Curative Resection of Hepatocellular Carcinoma
The aim of this study is to evaluate the effect of traditional Chinese medicine Babaodan on tumor recurrence of hepatocellular carcinoma after curative resection, as well as the safety of this treatment
- Trial name
- NCT03515369
- Testing
- Babaodan oral capsule
- Volunteers
- 459 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Cancer
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00096083
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Delcath Systems Inc.
Liver Transplantation, Hepatocellular Carcinoma
Impact of Postoperative Adjuvant Chemotherapy in Patients With Hepatocellular Carcinoma After Liver Transplantation
The study is designed to investigate the effect of postoperative adjuvant chemotherapy in prevention of tumor recurrence and metastasis for hepatocellular carcinoma after liver transplantation.
- Conditions
- Liver Transplantation, Hepatocellular Carcinoma, Tumor Recurrence and Metastasis, Survival
- Trial name
- NCT01125020
- Testing
- gemcitabine and oxaliplatin, doxorubicin, 5-Fu and cisplatin
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Hepatocellular Carcinoma
Postoperative Adjuvant Therapy With Recombinant Interferon-Alpha Following Curative Resection of HCC
We conducted a randomized controlled trial of adjuvant interferon therapy in patients with predominantly hepatitis B-related hepatocellular carcinoma (HCC) to investigate whether the prognosis after hepatic resection could be…
- Trial name
- NCT00234182
- Testing
- Interferon alpha-2b
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Breast Cancer, Colorectal Cancer
Biological Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I trial to study the effectiveness of biological therapy in treating patients who have…
- Conditions
- Breast Cancer, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00004604
- Testing
- CEA RNA-pulsed DC cancer vaccine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Duke University
Hepatocellular Carcinoma, Liver Cirrhosis
Study of Factors Predicting Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma (HCC)
Results of liver transplantation, the best theoretical treatment for HCC, are limited by tumor recurrence. In order to limit this risk Milan criteria was proposed in 1996.
- Conditions
- Hepatocellular Carcinoma, Liver Cirrhosis, Evidence of Liver Transplantation
- Trial name
- EFAPRE (NCT01198704)
- Testing
- search of factors predicting tumor recurrence
- Where
- France
- Volunteers
- 372 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma, Hepatitis B Virus
Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma
Most hepatocellular carcinomas are associated with hepatitis B virus, it is hypothesized that anti-viral treatment may be helpful in treating HBV-related hepatocellular carcinoma.
- Conditions
- Hepatocellular Carcinoma, Hepatitis B Virus, Recurrence
- Trial name
- NCT00768157
- Testing
- antiviral treatment (lamivudine or entecavir), radical resection of HBV-related HCC
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Liver Carcinoma
Hepatocellular Carcinoma Treated With Iodine-125 Implantation
To prospectively evaluate whether use of combined radiofrequency ablation (RFA) and percutaneous iodine-125 (125I) seeds implantation results in better survival compared with use of RFA alone in patients with hepatocellular…
- Trial name
- NCT01717729
- Testing
- Radiofrequency Ablation, iodine
- Volunteers
- 136 people
- Sponsor
- The Second People's Hospital of GuangDong Province
Hepatocellular Carcinoma Stage I, Recurrence
Impact of Hepatectomy on HCC Recurrence
Hepatectomy is the first option for the treatment of hepatocellular carcinoma(HCC) at CNLC Ib stage. HCC patients who undergo curative hepatectomy may experience varying remnant liver volumes and thus leads to different…
- Trial name
- HCC (NCT06390228)
- Testing
- Major hepatectomy
- Where
- China
- Volunteers
- 197 people
- Sponsor
- Anhui Medical University
Hepatocellular Carcinoma, Adjuvant Therapy
A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
This is an open label, multi-center, phaseⅡstudy to evaluate the efficacy and safety of TACE sequential tislelizumab as adjuvant therapy in hepatocellular carcinoma (HCC) patients who are at high risk of recurrence after curative…
- Trial name
- NCT04981665
- Testing
- Tislelizumab, TACE
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang University
Cancer
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients
RATIONALE: Palliative care may help patients with advanced cancer live more comfortably. PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a…
- Trial name
- NCT00253383
- Testing
- counseling intervention, educational intervention, psychosocial assessment and care
- Where
- 2 sites in United States
- Volunteers
- 329 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer
Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers
This phase II trial is studying how well giving cediranib maleate together with combination chemotherapy works in treating patients with advanced biliary cancers.
- Conditions
- Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder
- Trial name
- NCT01229111
- Testing
- cediranib maleate, oxaliplatin, leucovorin calcium
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer.
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor
- Trial name
- NCT00087191
- Testing
- EF5, motexafin lutetium, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma Recurrent, Surgery
Risk Factors, Prognosis, and Potential Chemoprevention Drugs in Patients With Recurrent Hepatocellular Carcinoma After Curative Surgeries: a Nationwide Retrospective Cohort Study and a Multi-center Prospective Cohort Analysis
Backgrounds: Surgeries are the mainstream of curative therapies for hepatocellular carcinoma (HCC). However, high risk of recurrent HCC after liver surgeries is still the unsolved clinical issue (early recurrence 21% per year…
- Trial name
- NCT05990959
- Testing
- No intervention for research purpose
- Where
- Taiwan
- Volunteers
- 800 people
- Sponsor
- China Medical University Hospital
Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder
Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
This phase II trial is studying how well bortezomib works as first-line systemic therapy in treating patients with unresectable locally advanced or metastatic adenocarcinoma (cancer) of the bile duct or gallbladder.
- Conditions
- Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Advanced Adult Primary Liver Cancer, Gastrointestinal Cancer
- Trial name
- NCT00085410
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Pain
- Trial name
- NCT00073905
- Testing
- capecitabine plus gemcitabine
- Where
- Switzerland
- Volunteers
- 44 people
- Sponsor
- Swiss Cancer Institute
Liver Cancer
Epirubicin and Thalidomide in Treating Patients With Liver Cancer
RATIONALE: Drugs used in chemotherapy such as epirubicin use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00058487
- Testing
- epirubicin hydrochloride, thalidomide
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute
Hepatocellular Carcinoma
The Influence of Resection Margin on the Recurrence of Early-stage Hepatocellular Carcinoma
Before the surgery, the investigators predict the risk of microvascular invasion (MVI) presence for the early-stage hepatocellular carcinoma according to the nomogram the investigators have created.
- Trial name
- NCT02525965
- Testing
- Wide resection margin >1cm, Narrow resection margin <1cm
- Where
- China
- Volunteers
- 194 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma, Adjuvant
Adjuvant TACE in HCC With High-risk Recurrence Factors
The 5-year recurrence rate after curative hepatectomy of hepatocellular carcinoma (HCC) remains as high as 70%. According to the Chinese Liver Cancer Staging (CNLC), transarterial chemoembolization (TACE) is strongly recommended…
- Conditions
- Hepatocellular Carcinoma, Adjuvant, Transarterial Chemoembolization
- Trial name
- NCT07417397
- Testing
- Adjuvant transarterial chemoembolization, Intensive follow-up
- Where
- China
- Volunteers
- 442 people
- Sponsor
- Guangxi Medical University
Hepatocellular Carcinoma
Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Partial hepatectomy is still considered as the conventional therapy for HCC.
- Trial name
- NCT01570166
- Testing
- HR, RFA
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Sun Yat-sen University